Experimental models that faithfully mimic the developmental pathology of sporadic
Alzheimer's disease (sAD) in humans are important for testing the novel therapeutic …

Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …

Brain metastases present mostly multifocal, infiltrative and co-opting growth with the blood-
brain barrier (BBB) remaining intact. The BBB, as the barrier of drug delivery to such lesions …

Animal models for learning and memory have significantly contributed to novel strategies for
drug development and hence are an imperative part in the assessment of therapeutics …

Recent advances in the understanding of the pathophysiological mechanisms underlying
Alzheimer's disease and other cognitive deficits have pointed to novel strategies for drug …

Metformin (Met) is used to treat neurodegenerative disorders such as Alzheimer's disease
(AD). Conversely, high-fat diets (HFD) have been shown to increase AD risk. In this study …

The aim of this study was to examine the effect of simvastatin (SMV), a 3-hydroxy-3-methyl-
glutaryl-CoA reductase inhibitor, in rats fed with a standard or a high-fat diet (HFD) …

Rett syndrome (RTT), an X-linked neurological disorder caused by mutations in MECP2,
may have a metabolic component. We reported a genetic suppressor screen in a Mecp2-null …

Cognitive function is impaired by imbalanced diet consumption. High-fat diet (HFD) induces
oxidative stress and metabolic disorders, which results in neuronal damage and interferes …

High-fat diet is a major causative factor of overweight and obesity, which are associated with
an increased risk of neuropsychiatric diseases, such as anxiety and depression. In the …